NJHA is offering a complimentary webinar, Anticoagulant Education for Patients Diagnosed with VTE, Oct. 30 from 12 noon to 1 p.m.
Each year, between 300,000 and 600,000 Americans are affected by venous thromboembolism (VTE), the formation of blood clots in the vein, including deep vein thrombosis (DVT) and pulmonary embolism (PE). The incidence of VTE is projected to double in the next 40 years, making VTE a concern for a broad range of clinicians. World Thrombosis Day, observed Oct. 13, has been organized to encourage awareness of these deadly complications.
For many years, discharge instructions for VTE have included medication management recommendations related to the use of warfarin. However, the introduction of direct oral anticoagulants (DOACs) has catalyzed significant changes in the therapeutic landscape of VTE treatment. This makes it imperative that clinicians become familiar with new treatment paradigms and offer appropriate patient education.
The program will discuss:
- DOAC limitations and use in routine clinical care, and
- The Joint Commission’s discharge instructions and education materials for venous thromboembolism, A Comprehensive Approach to Medication Management.
Continuing medical education, nurse and pharmacy credits will be provided.
Click here to register.